Ranbaxy Labs gained by 1% at Rs 440 on reports that its wholly-owned subsidiary -- Ranbaxy Pharmaceuticals has launched an authorised generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin.
Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.
In intra-day deals, the stock opened at Rs 441.95 and touched the high of Rs 444.10. The counter has seen trades around 69,637 shares so far on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app